Seaside Therapeutics, Inc.
14
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
35.7%
5 terminated/withdrawn out of 14 trials
61.5%
-25.0% vs industry average
29%
4 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers
Role: collaborator
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Role: lead
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Role: lead
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Role: lead
An Open Label Extension Study in Subjects With Fragile X Syndrome
Role: lead
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Role: lead
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Role: lead
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Role: lead
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Role: lead
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Role: lead
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Role: lead
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
Role: lead
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Role: lead
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
Role: lead
All 14 trials loaded